The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,194
- 试验地点
- 1
- 主要终点
- Cardiovascular events
研究概览
简要总结
This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.
详细描述
Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-valvular atrial fibrillation
- •Receiving oral anticoagulation therapy and have good compliance
排除标准
- •Life expectancy less than 1 year
- •Thrombosis or major bleeding history within 3 months
- •Refusal to Participate
研究组 & 干预措施
Dabigatran Group
Patiets with atrial fibrillation received dabigatran (110mg, bid).
干预措施: Dabigatran Etexilate 110mg (Drug)
Warfarin Group
Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
干预措施: Warfarin Sodium (Drug)
结局指标
主要结局
Cardiovascular events
时间窗: 12 months
Thrombotic events, cardiovascular deaths, major bleeding events
次要结局
未报告次要终点